An observational study in Cancer, sponsored by Centre Antoine Lacassagne. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Centre Antoine Lacassagne · Observational
Research into biomarkers predictive of survival and response to cancer treatment
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 40,000 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Centre Antoine Lacassagne is the lead sponsor of 66 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with cancer receiving care at Centre Antoine Lacassagne are prospectively recruited for biospecimen collection during routine clinical blood sampling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
blood sampling
Other: blood sampling
36ml of blood will be taken during a blood sampling performed in standard practice
Prediction
The aim of this project is to make a biobank in prevision of MR004 sub-projects which define specific biomarkers studied to identify biomarkers predictive of response.
Time frame: day 1
Plan to share: Yes — pseudonymised data will only be collected
Supporting information: Study protocol, Clinical study report
Time frame: at the end of study
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Antoine Lacassagne